Practical management of patients on anti-IL17 therapy: Practical guidelines drawn up by the Club Rhumatismes et Inflammation (CRI)-Reference-Cited by-同舟云学术

Practical management of patients on anti-IL17 therapy: Practical guidelines drawn up by the Club Rhumatismes et Inflammation (CRI)

Published:2021-05 Issue:3 Volume:88 Page:105210
ISSN:1297-319X
Container-title:Joint Bone Spine
language:en
Short-container-title:Joint Bone Spine

Author:

Tournadre Anne,Sellam Jérémie,Morel Jacques,Jullien Denis,Bouhnik Yoram,Cornec Divi,Devauchelle-Pensec Valérie,Goupille Philippe,Kluger Nicolas,Lazaro Estibaliz,Goff Benoit Le,Lédinghen Victor de,Lequerré Thierry,Nocturne Gaëtane,Seror Raphaèle,Truchetet Marie-Elise,Verhoeven Frank,Richez Christophe,Pham Thao

Publisher

Elsevier BV

Subject

Rheumatology

Reference180 articles.

1. Efficacy of secukinumab without the initial weekly loading dose in patients with chronic plaque psoriasis;Gisondi;Br J Dermatol,2020

2. Efficacy and Safety of Subcutaneous Secukinumab 150 mg with or Without Loading Regimen in Psoriatic Arthritis: Results from the FUTURE 4 Study;Kivitz;Rheumatol Ther,2019

3. Efficacy and Safety of Secukinumab 150 mg with and Without Loading Regimen in Ankylosing Spondylitis: 104-week Results from MEASURE 4 Study;Kivitz;Rheumatol Ther,2018

4. Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study;Mease;Ann Rheum Dis,2018

5. Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial